# E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events

> **NCT00345839** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 3883 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Chronic Kidney Disease

## Interventions

- **DRUG:** Cinacalcet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00345839
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-22
- **Primary completion:** 2012-04-10
- **Final completion:** 2012-04-10
- **Target enrollment:** 3883 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345839, "E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00345839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*